Fever of unknown origin: atypical presentation of Parkinson's disease
DOI:
https://doi.org/10.32818/reccmi.a8n3a5Keywords:
fever of unknown origin, primary dysautonomias, parkinsonian disorders, levodopaAbstract
We present a 74-year-old female patient who was admitted to the hospital for evaluation of fever and deterioration of her general condition. Complementary tests focused on the differential diagnosis of fever of unknown origin were negative. Given the progressive neurological worsening with bradypsychia, bradylalia, mutism, rigidity, and symptoms of severe dysautonomia, a provocation test with levodopa was performed on suspicion of parkinsonism. The patient's evolution after treatment was very favorable, with disappearance of the fever, the neurological and other dysautonomia symptoms.
Downloads
Metrics
References
Haidar G, Singh N. Fever of unknown origin. N Engl J Med. 2022; 386(5): 463–477. doi: https://doi.org/10.1056/nejmra2111003 (último acceso oct. 2023). DOI: https://doi.org/10.1056/NEJMra2111003
Cunha BA, Lortholary O, Cunha CB. Fever of unknown origin: a clinical approach. Am J Med. 2015; 128(10): 1138.e1-1138.e15. doi: https://doi.org/10.1016/j.amjmed.2015.06.001 (último acceso oct. 2023). DOI: https://doi.org/10.1016/j.amjmed.2015.06.001
Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007; 164(6): 870–876. doi: https://doi.org/10.1176/ajp.2007.164.6.870 (último acceso oct. 2023). DOI: https://doi.org/10.1176/ajp.2007.164.6.870
Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013; 13(4): 533-540. Accesible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865832/ (último acceso oct. 2023).
Castillo E, Rubin RT, Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry. 1989; 146(3): 324–328. doi: https://doi-org/10.1176/ajp.146.3.324 (último acceso oct. 2023). DOI: https://doi.org/10.1176/ajp.146.3.324
Newman, EJ, Grosset, DG, Kennedy, PGE. The Parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009; 10: 136–140. doi: https://doi.org/10.1007/s12028-008-9125-4 (último acceso oct. 2023). DOI: https://doi.org/10.1007/s12028-008-9125-4
Mendoza-Velásquez JJ, Flores-Vázquez JF, Barrón-Velázquez E, Sosa-Ortiz AL, Illigens B-MW, Siepmann T. Autonomic dysfunction in α-synucleinopathies. Front Neurol. 2019; 10: 363. doi: https://doi.org/10.3389/fneur.2019.00363 (último acceso oct. 2023). DOI: https://doi.org/10.3389/fneur.2019.00363
Rossi P, Colosimo C, Moro E, Tonali P, Albanese A. Acute challenge with apomorphine and levodopa in Parkinsonism. Eur Neurol. 2000; 43(2): 95–101. doi: https://doi.org/10.1159/000008142 (último acceso oct. 2023). DOI: https://doi.org/10.1159/000008142
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Clara Marín Barbancho, Rebeca García-Caballero
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
